newsfilter
← Latest News
PR Newswire·

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

  • Cardiol Therapeutics received over USD $7 million from the exercise of outstanding common share purchase warrants.
  • The capital raised extends the company's cash runway into the first half of 2028.
  • Funds will support operations through the pivotal Phase III MAVERIC trial data readout for CardiolRx™ in recurrent pericarditis.
  • Proceeds will also provide working capital flexibility & fund regulatory preparations for a potential New Drug Application.
  • The company exercised its Acceleration Right pursuant to warrants issued in October 2025, with 425,000 warrants remaining unexercised as of September 15, 2026.
  • Unexercised warrants will expire at 4:00 p.m. Eastern Time on October 16, 2026, & any remaining warrants will be automatically cancelled.
  • CardiolRx™ targets the inflammasome pathway for inflammatory heart diseases including pericarditis, myocarditis, & heart failure.
  • The MAVERIC program includes the completed Phase II MAvERIC-Pilot study & the ongoing Phase III trial for recurrent pericarditis.
  • The ARCHER program previously evaluated CardiolRx™ in acute myocarditis & the company is developing a subcutaneous formulation named CRD-38 for inflammatory heart disease.